In a recent IDC Spotlight report, Dr. Nimita Limaye explores how digital biomarkers are changing the life sciences and healthcare landscape, driving improvements in clinical trial patient recruitment, clinical trial design and predictive/preventative care.
“The ability to combine insights from both digital and clinical biomarkers, and to obtain a holistic understanding of a patient’s health, holds enormous promise,” observes Dr. Limaye. She notes that the digital biomarker market has seen double digit growth, in part because digital biomarkers deliver noninvasive, passive, continuous measurement, and are a key enabler of remote and decentralized clinical trials.
Dr. Limaye emphasizes the role of robust biomarker hubs in driving digital innovation: “A biomarker hub that can integrate these diverse types of biomarker data and tap into phenotypic and digital real-world data (RWD) provides powerful synergies to drive clinical trial strategy, inform clinical trial design, and drive portfolio management decisions.”
Dr. Limaye points to AI/ML and cloud computing, in particular, as technologies that will enable hyperscalers to transform massive amounts of data into meaningful intelligence that drives treatment decisions.